ES2063769T3 - DNA CLONE OF THE HUMAN TISSUE FACTOR INHIBITOR. - Google Patents

DNA CLONE OF THE HUMAN TISSUE FACTOR INHIBITOR.

Info

Publication number
ES2063769T3
ES2063769T3 ES88870127T ES88870127T ES2063769T3 ES 2063769 T3 ES2063769 T3 ES 2063769T3 ES 88870127 T ES88870127 T ES 88870127T ES 88870127 T ES88870127 T ES 88870127T ES 2063769 T3 ES2063769 T3 ES 2063769T3
Authority
ES
Spain
Prior art keywords
human tissue
tissue factor
dna clone
factor inhibitor
clone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88870127T
Other languages
Spanish (es)
Inventor
George John Broze Jr
Kuniko Kusano Kretzmer
Tze-Chein Wun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Washington University in St Louis WUSTL
Monsanto Co
Original Assignee
University of Washington
Washington University in St Louis WUSTL
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22410671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2063769(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/123,753 external-priority patent/US4966852A/en
Application filed by University of Washington, Washington University in St Louis WUSTL, Monsanto Co filed Critical University of Washington
Application granted granted Critical
Publication of ES2063769T3 publication Critical patent/ES2063769T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

UN CLON DE ADNC QUE TIENE UNA SECUENCIA BASE PARA EL FACTOR DE INHIBICION DE TEJIDO HUMANO (TFI) HA SIDO DESARROLLADO Y CARACTERIZADO Y SE HA DETERMINADO LA SECUENCIA AMINOACIDA DEL TFIU.A cDNA CLONE THAT HAS A BASE SEQUENCE FOR THE HUMAN TISSUE INHIBITION FACTOR (TFI) HAS BEEN DEVELOPED AND CHARACTERIZED AND THE AMINO ACID SEQUENCE OF TFIU HAS BEEN DETERMINED.

ES88870127T 1987-11-23 1988-07-22 DNA CLONE OF THE HUMAN TISSUE FACTOR INHIBITOR. Expired - Lifetime ES2063769T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/123,753 US4966852A (en) 1987-07-23 1987-11-23 DNA clone of human tissue factor inhibitor

Publications (1)

Publication Number Publication Date
ES2063769T3 true ES2063769T3 (en) 1995-01-16

Family

ID=22410671

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88870127T Expired - Lifetime ES2063769T3 (en) 1987-11-23 1988-07-22 DNA CLONE OF THE HUMAN TISSUE FACTOR INHIBITOR.

Country Status (15)

Country Link
EP (1) EP0318451B1 (en)
JP (5) JP2836823B2 (en)
KR (1) KR930000274B1 (en)
AT (1) ATE111518T1 (en)
AU (1) AU604139B2 (en)
CA (1) CA1341223C (en)
DE (1) DE3851511T2 (en)
DK (1) DK173536B1 (en)
ES (1) ES2063769T3 (en)
FI (1) FI93365C (en)
IE (1) IE65393B1 (en)
IL (1) IL87171A (en)
NO (2) NO310466B1 (en)
NZ (1) NZ225535A (en)
PT (1) PT88076B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378614A (en) * 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
DK408089D0 (en) * 1989-08-18 1989-08-18 Novo Nordisk As PROTEINS
EP0439442B1 (en) * 1990-01-25 1996-03-06 Washington University Factor x-laci hybrid protein
CA2049873C (en) * 1990-08-27 2001-12-04 Tze-Chein Wun Anticoagulant combination of laci and sulfated polysaccharides
DK261490D0 (en) * 1990-10-31 1990-10-31 Novo Nordisk As NEW PHARMACEUTICAL COMPOUND
US5346991A (en) * 1991-06-13 1994-09-13 Genentech, Inc. Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
US5276015A (en) * 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
US20030171292A1 (en) 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
IL161407A0 (en) 2001-10-15 2004-09-27 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DK2311432T3 (en) 2002-06-07 2015-02-02 Dyax Corp Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US8828703B2 (en) 2005-12-29 2014-09-09 Dyax Corp. Protease inhibition
CA2747721C (en) 2008-12-19 2021-07-20 Baxter International Inc. Tfpi inhibitors and methods of use
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
ES2688093T3 (en) 2010-01-06 2018-10-30 Dyax Corp. Plasma kallikrein binding proteins
EP2547355B1 (en) 2010-03-19 2017-01-11 Baxalta GmbH Tfpi inhibitors and methods of use
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp KALLIKREIN PLASMA BINDING PROTEINS
MY166974A (en) 2011-06-15 2018-07-27 Hoffmann La Roche Anti-human epo receptor antibodies and method of use
EP2827883B1 (en) 2012-03-21 2019-05-08 Baxalta GmbH Tfpi inhibitors and methods of use
BR112018011622A2 (en) 2015-12-11 2018-11-27 Dyax Corp method to treat hereditary angioedema attack (hae) or reduce hae attack rate
CA3167336A1 (en) 2020-01-13 2021-07-22 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
IL87172A (en) * 1987-07-23 1994-12-29 Univ Washington Method of isolating highly purified tissue factor inhibitor

Also Published As

Publication number Publication date
JP2002097200A (en) 2002-04-02
JP2836823B2 (en) 1998-12-14
DK413488A (en) 1989-05-24
FI93365C (en) 1995-03-27
EP0318451A3 (en) 1990-03-28
JP2004201696A (en) 2004-07-22
JP3565714B2 (en) 2004-09-15
KR930000274B1 (en) 1993-01-14
FI883487L (en) 1989-05-24
IE65393B1 (en) 1995-10-18
KR890007750A (en) 1989-07-05
DK173536B1 (en) 2001-02-05
PT88076B (en) 1993-01-29
JPH01165383A (en) 1989-06-29
JP2005306875A (en) 2005-11-04
IL87171A0 (en) 1988-12-30
IE882243L (en) 1989-05-23
FI93365B (en) 1994-12-15
AU1928788A (en) 1989-05-25
EP0318451A2 (en) 1989-05-31
DK413488D0 (en) 1988-07-22
FI883487A0 (en) 1988-07-22
DE3851511D1 (en) 1994-10-20
EP0318451B1 (en) 1994-09-14
NO20013608D0 (en) 2001-07-20
AU604139B2 (en) 1990-12-06
PT88076A (en) 1988-08-01
JPH1175875A (en) 1999-03-23
NO883270L (en) 1989-05-24
NO310466B1 (en) 2001-07-09
IL87171A (en) 1995-08-31
NZ225535A (en) 1990-11-27
NO883270D0 (en) 1988-07-22
JP4025035B2 (en) 2007-12-19
CA1341223C (en) 2001-05-01
DE3851511T2 (en) 1995-03-30
NO20013608L (en) 1989-05-24
ATE111518T1 (en) 1994-09-15

Similar Documents

Publication Publication Date Title
NO20013608D0 (en) DNA Clone for Human Tissue Factor Inhibitor
ES2031806T3 (en) HUMAN VASCULAR PERMEABILITY FACTOR.
BR8707937A (en) PROSTHESIS FOR OSTEOSYNTHESIS
NO882472D0 (en) PROCEDURE FOR THE PREPARATION OF PEPTID DRILL ACID INHIBITORS FOR TRYP SIMILAR PROTASES.
ES2040727T3 (en) A PROCESS TO PREPARE A FORMULATION IN AEROSOL IN SOLUTION OF AN ANALOG.
DE3888570D1 (en) Magnetic ankle replacing prosthesis.
AR002043A1 (en) USE OF ALPHA AGONISTS (1L) FOR THE TREATMENT OF URINARY INCONTINENCE.
DK437188D0 (en) PROCEDURE FOR CRYPEROUSING OF THE HEART VALVE
ES2053778T3 (en) PROCEDURE FOR THE OBTAINING OF TIAZOL DERIVATIVES.
ES2041705T3 (en) PROCEDURE FOR THE PREPARATION OF 1- (4-HYDROXY-3,5-DI-TERC-BUTYL-BENZOIL) -HOMOPIPERAZINE AND ITS DERIVATIVES.
DK0417003T3 (en) Use of antiprogestomimetic compounds to promote ovulation
ES2036627T3 (en) PROCEDURE FOR THE PREPARATION OF BICYCLIC ALDEHYDES.
DK183582A (en) PROCEDURE FOR THE PREPARATION OF OXAZOLD DERIVATIVES
ES547724A0 (en) A PROCEDURE FOR PREPARING OXADIAZOLIL-1,4-DIHIDROPIRI-DINAS AND ITS ANALOGUE COMPOUNDS
IT1199114B (en) DROERGOTOXINE-BASED PHARMACEUTICAL COMPOUND FOR THE TREATMENT OF HYPERTENSION
NO885645L (en) PROTECTIVE COATING OF THE BURNED ANODES AND THE PROJECTING PART OF THE ANODS.
ES8501757A1 (en) PROCEDURE FOR OBTAINING 5-DIAZACICLOALQUILIMIDAZO- (1,2-C) - (1,3) -BENZODIAZEPINAS.
ES2017589A4 (en) PACKAGING FOR SURGICAL LIGATURES AND SUBSTRATES IN THE FORM OF A CASE.
IT1219040B (en) ENDOLUMINAL EXPANSION PROSTHESIS ESPECIALLY FOR THE TREATMENT OF VASCULAR DISEASES
IT8719433A0 (en) PROCEDURE FOR THE PREPARATION OF HUMAN ALPHAFETOPROTEIN.
IT9048106A0 (en) MEDICINAL ASSOCIATION FOR THE TREATMENT OF HYPERTENSION AND CONGESTIVE HEART FAILURE. (CASE 100-7516)
IT8767911A0 (en) FLUSH FOR THE FORMATION OF DENTAL PROSTHESES
ES1001672Y (en) FOOTWEAR LAST
IT8721299A0 (en) PROCEDURE FOR THE HYDROPHOBISATION OF PLASTER OBJECTS.
IT1212555B (en) CALCIUM DOBESILATE-BASED COMPOSITION FOR THE TREATMENT OF HEART DISEASES

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 318451

Country of ref document: ES